The Cancer Clinical Research Office (CCRO) provides experienced and proficient coordination, administration, and reporting for all cancer clinical trials conducted at the Mayo Clinic Cancer Center (MCCC). The primary services provided by the CCRO, which include protocol development and maintenance, compliance, study coordination, and training/education, are fundamental to the clinical research activities of the MCCC. Staff in the CCRO work collaboratively with each MCCC program and many of the MCCC shared resources to provide expert, efficient support in the conduct of clinical research. The CCRO consists of four main areas which are integrated together to form an efficient, organized resource. The four areas are: 1) Protocol Management, which includes the development and maintenance of all protocol documents and the entry of protocol-specific data into the MCCC database for the purpose of tracking and reporting of study information;2) Study Coordination, which includes the screening, enrolling, and management of clinical trial participants;3) Compliance, which includes auditing, monitoring, and providing regulatory expertise;and 4) Quality Control, which includes training and education and ensuring data quality. These areas work effectively together on a daily basis to provide clinical trial collaboration, support, management, and dissemination of information to investigators and programs across the Mayo enterprise. Dr. Steven Alberts and Kelly Paulson are Co-Directors of the CCRO. A prominent attribute of the CCRO is the extensive integration and standardization among the MCCC campuses to provide collaborative support to MCCC investigators and programs. The integration of the MCCC across the Mayo enterprise (Arizona, Florida, Rochester) has required a unified CCRO, which consists of shared systems, standard operating procedures, structure, support, and the ability to provide cross-coverage in support of MCCC investigators. Future goals of the CCRO include continued efforts to improve the timelines, development, activation, and conduct of clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications